Pascal and Francis Bibliographic Databases

Help

Search results

Your search

au.\*:("Parkinson's Disease Foundation")

Document Type [dt]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 58

  • Page / 3
Export

Selection :

  • and

3 rd Canadian conference on neurodegenerative diseases, L'Estérel PQ, April 4-6, 1991CALNE, D.Canadian journal of neurological sciences. 1992, Vol 19, Num 1, issn 0317-1671, SUPConference Proceedings

Synergistic interactions of D1- and D2-selective dopamine agonists in animal models for Parkinson's disease : sites of action and implications for the pathogenesis of dyskinesiasROBERTSON, H. A.Canadian journal of neurological sciences. 1992, Vol 19, Num 1, pp 147-152, issn 0317-1671, SUPConference Paper

A rationale for dopamine agonists as primary therapy for Parkinson's diseaseOLANOW, C. W.Canadian journal of neurological sciences. 1992, Vol 19, Num 1, pp 108-112, issn 0317-1671, SUPConference Paper

The place of the dopaminergic agonists in the treatment of Parkinson's disease the view from thye trenchesKING, D. B.Canadian journal of neurological sciences. 1992, Vol 19, Num 1, pp 156-159, issn 0317-1671, SUPConference Paper

Amyotrophic lateral sclerosis, Parkinson's disease and Alzheimer's disease : phylogenetic disorders of the human neocortex sharing many characteristicsEISEN, A; CALNE, D.Canadian journal of neurological sciences. 1992, Vol 19, Num 1, pp 117-123, issn 0317-1671, SUPConference Paper

Future treatment of Parkinson's diseaseKING CHING TSUI, J.Canadian journal of neurological sciences. 1992, Vol 19, Num 1, pp 160-162, issn 0317-1671, SUPConference Paper

Positron emission tomography in Parkinson's diseaseSNOW, B. J.Canadian journal of neurological sciences. 1992, Vol 19, Num 1, pp 138-141, issn 0317-1671, SUPConference Paper

Prevention and management of late stage complications in Parkinson's diseaseSTOESSL, A. J.Canadian journal of neurological sciences. 1992, Vol 19, Num 1, pp 113-116, issn 0317-1671, SUPConference Paper

Sustained release antiparkinson agents : controlled release levodopaGAUTHIER, S; AMYOT, D.Canadian journal of neurological sciences. 1992, Vol 19, Num 1, pp 153-155, issn 0317-1671, SUPConference Paper

Frequency and cause of Parkinson's diseaseRAJPUT, A. H.Canadian journal of neurological sciences. 1992, Vol 19, Num 1, pp 103-107, issn 0317-1671, SUPConference Paper

Understanding Disability in Parkinson's DiseaseSHULMAN, Lisa M.Movement disorders. 2010, Vol 25, Num 3, issn 0885-3185, S131-S135, SUP1Conference Paper

Cognitive Impairment and Dementia in Parkinson's DiseaseMARDER, Karen.Movement disorders. 2010, Vol 25, Num 3, issn 0885-3185, S110-S116, SUP1Conference Paper

Inflammation and Parkinson's Disease PathogenesisPRZEDBORSKI, Serge.Movement disorders. 2010, Vol 25, Num 3, issn 0885-3185, S55-S57, SUP1Conference Paper

Frontiers in Parkinson's Disease. SymposiumFAHN, Stanley; BURKE, Robert E; MAYEUX, Richard et al.Movement disorders. 1998, Vol 13, issn 0885-3185, 97 p., SUP1Conference Proceedings

A preclinical development strategy designed to optimize the use of glial cell line-derived neurotrophic factor in the treatment of Parkinson's diseaseLAPCHAK, P. A.Movement disorders. 1998, Vol 13, pp 49-54, issn 0885-3185, SUP1Conference Paper

Frontiers of Science and Clinical Advances in Quality of Life in Parkinson's DiseaseFAHN, Stanley; MARDER, Karen; COTE, Lucien et al.Movement disorders. 2010, Vol 25, Num 3, issn 0885-3185, 183 p., SUP1Conference Proceedings

Advances in Environmental EpidemiologyTANNER, Caroline M.Movement disorders. 2010, Vol 25, Num 3, issn 0885-3185, S58-S62, SUP1Conference Paper

Clues to How Alpha-Synuclein Damages Neurons in Parkinson's DiseaseSULZER, David.Movement disorders. 2010, Vol 25, Num 3, issn 0885-3185, S27-S31, SUP1Conference Paper

Oxidative mechanisms in nigral cell death in Parkinson's diseaseJENNER, P.Movement disorders. 1998, Vol 13, pp 24-34, issn 0885-3185, SUP1Conference Paper

Programmed cell death and Parkinson's diseaseBURKE, R. E.Movement disorders. 1998, Vol 13, pp 17-23, issn 0885-3185, SUP1Conference Paper

Deprenyl in Parkinson's disease : mechanisms, neuroprotective effect, indications and adverse effectsVEZINA, P; MOHR, E; GRIMES, D et al.Canadian journal of neurological sciences. 1992, Vol 19, Num 1, pp 142-146, issn 0317-1671, SUPConference Paper

DJ-1, PINK 1, and Their Effects on Mitochondrial PathwaysCOOKSON, Mark R.Movement disorders. 2010, Vol 25, Num 3, issn 0885-3185, S44-S48, SUP1Conference Paper

Evaluation of the Braak Staging Scheme for Parkinson's disease: Introduction to a Panel PresentationBURKE, Robert E.Movement disorders. 2010, Vol 25, Num 3, issn 0885-3185, S76-S77, SUP1Conference Paper

Gastrointestinal, Urological, and Sexual Dysfunction in Parkinson's DiseasePFEIFFER, Ronald F.Movement disorders. 2010, Vol 25, Num 3, issn 0885-3185, S94-S97, SUP1Conference Paper

New Developments in Depression, Anxiety, Compulsiveness, and Hallucinations in Parkinson's DiseaseGOETZ, Christopher G.Movement disorders. 2010, Vol 25, Num 3, issn 0885-3185, S104-S109, SUP1Conference Paper

  • Page / 3